

## Liver Transplant Recipient Registration (TRR) Record Field Descriptions

The Transplant Recipient Registration (TRR) records are generated and available immediately after a transplant event is reported through the recipient feedback process in Waitlist<sup>SM</sup>. A TRR will also be generated in the case of a living donor transplant, where a recipient was added through the donor feedback process in Tiedi<sup>®</sup>. The TRR record is completed by the transplant center performing the transplant. The registration and hospital discharge follow-up information is combined in this record.

**Complete the TRR at hospital discharge or six weeks post transplant, whichever is first.** If the recipient is still hospitalized at six weeks post transplant, provide the most recent information available regarding the recipient's progress.

The TRR record must be completed within 60 days from the record generation date. See [OPTN Policy Submission Requirements](#) for additional information. Use the search feature to locate specific policy information on Data Submission Requirements.

To correct information that is already displayed on an electronic record, call the UNet<sup>SM</sup> Help Desk at 1-800-978-4334.

### Recipient Information

**Name:** Verify the last name, first name and middle initial of the transplant recipient is correct. If the information is incorrect, corrections may be made on the recipient's TCR record.

**DOB:** Verify the displayed date is the recipient's date of birth. If the information is incorrect, corrections may be made on the recipient's TCR record.

**SSN:** Verify the recipient's social security number is correct. If the information is incorrect, contact the Help Desk at 1-800-978-4334.

**Gender:** Verify the recipient's gender is correct. If the information is incorrect, corrections may be made on the recipient's TCR record.

**HIC:** Verify the 9 to 11 character Health Insurance Claim number for the recipient indicated on the recipient's most recently updated TCR record is correct. If the recipient does not have a HIC number, you may leave this field blank.

**Tx Date:** Verify the displayed transplant date is the date of the beginning of the first anastomosis. If the operation started in the evening and the first anastomosis began early the next morning, the transplant date is the date that the first anastomosis began. The transplant is considered complete when the cavity is closed and the final skin stitch/staple is applied. The transplant date is indicated immediately after a transplant event is reported through the recipient feedback process in Waitlist and in the case of a living donor transplant, where a recipient was added through the donor feedback process in Tiedi.

**State of Permanent Residence:** Select the name of the state of the recipient's permanent address at the time of transplant (location of full-time resident, not transplant center location). This field is **required**. ([List of State codes – See Appendix A](#))

**Permanent Zip Code:** Enter the recipient's permanent zip code at the time of transplant (location of full-time residence, not transplant center location). This field is **required**.

### Provider Information

**Recipient Center:** The Recipient Center information reported in Waitlist displays. Verify that the center information is the hospital where the transplant operation was performed. The Provider Number is the 6-character Medicare identification number of the hospital. This is followed by the Center Code and Center Name.

**Surgeon Name:** Enter the name of the primary surgeon, who performed the transplant operation, and under whose name the transplant is billed. This field is **required**.

**Surgeon NPI #:** Enter the 10-character CMS (Center for Medicare and Medicaid Services) assigned National Provider Identifier of the transplant surgeon. Your hospital billing office may be able to obtain this number for you. This field is **required**.

## Donor Information

**UNOS Donor ID #:** The UNOS Donor ID number, reported in the Recipient Feedback, will display. Each potential donor is assigned an identification number by OPTN/UNOS. This ID number corresponds to the date the donor information was entered into the OPTN/UNOS computer system.

**Donor Type:** The donor type, reported in the Recipient Feedback, will display. Verify the recipient's donor type is correct. If the information is incorrect, contact the Help Desk at 1-800-978-4334.

**Deceased** indicates the donor was not living at the time of donation.

**Living** indicates the donor was living at the time of donation.

## Patient Status

**Primary Diagnosis:** Select the primary diagnosis **for the disease requiring a transplant** for this recipient. If Other, Specify is selected, enter the primary diagnosis in the space provided. This field is **required**. ([List of Liver Diagnosis codes – See Appendix P](#))

**Date: Last Seen, Retransplanted or Death:** Complete at discharge (if discharged prior to six weeks from transplant date) or at six weeks from transplant date, whichever occurs first. Enter the date the hospital reported the recipient as living, retransplanted (when the data was obtained prior to the recipient's discharge) or the date of the recipient's death, using the standard 8-digit numeric format of MM/DD/YYYY. This field is **required**.

**Patient Status:** Complete at discharge (if discharged prior to six weeks from transplant date) or at six weeks from transplant date, whichever occurs first. Select the appropriate status for this recipient. If **Dead** is selected, indicate the cause of death. This field is **required**.

**Living**

**Dead**

**Retransplanted**

**Primary Cause of Death:** If the Patient Status is **Dead**, select the patient's cause of death. If an **Other** code is selected, enter the other cause of death in the space provided. ([List of Primary Cause of Death codes – See Appendix K](#))

**Contributory Cause of Death:** If the Patient Status is **Dead**, select the patient's contributory cause of death. If an **Other** code is selected, enter the other cause of death in the space provided. ([List of Contributory Cause of Death codes – See Appendix K](#))

**Contributory Cause of Death:** If the Patient Status is **Dead**, select the patient's contributory cause of death. If an **Other** code is selected, enter the other cause of death in the space provided. ([List of Contributory Cause of Death codes – See Appendix K](#))

**Note:** If the patient is being retransplanted, access the patient's last record for their previous transplant and select **Retransplanted** in the **Patient Status** field. This will stop the generation of TRF records associated with the previous transplant.

## Transplant Hospitalization:

**Date of Admission to Tx Center:** Enter the date the recipient was admitted to the transplant center, using the 8-digit MM/DD/YYYY format. If the patient was admitted to the hospital before it was determined a transplant was needed, enter the date it was determined the patient needed a transplant. This field is **required**.

**Date of Discharge From Tx Center:** Enter the date the recipient was released to go home, using the 8-digit MM/DD/YYYY format. The recipient's hospital stay includes total time spent in different units of the hospital, including medical and rehab. This information is not required in the TRR record, but if entered here, it will automatically fill in the future TRF records. It is required in the TRF record.

**Note:** Leave this field blank if the recipient was removed from the waiting list with a code of 21, indicating the recipient died during the transplant procedure.

### Clinical Information: PRETRANSPLANT

**Medical Condition at time of transplant:** Select the choice that best describes the recipient's condition and location just prior to the time of transplant. This field is **required**.

**In Intensive Care Unit**  
**Hospitalized Not in ICU**  
**Not Hospitalized**

**Patient on Life Support:** If the patient was on life support at the time of transplant, select **Yes**. If not, select **No**. If **Yes** is selected, check all that apply. If a type of life support used is not listed select **Other Mechanism, Specify** and specify the type in the space provided. This field is **required**.

**Ventilator** - Select only if the recipient is on continuous invasive ventilation  
**Artificial Liver**  
**Other Mechanism, Specify**

**Functional Status:** Select the choice that best describes the recipient's functional status just prior to the time of transplant. This field is **required**.

**Note:** The Karnofsky Index will display for adults aged 18 and older.

100% - Normal, no complaints, no evidence of disease  
90% - Able to carry on normal activity: minor symptoms of disease  
80% - Normal activity with effort: some symptoms of disease  
70% - Cares for self: unable to carry on normal activity or active work  
60% - Requires occasional assistance but is able to care for needs  
50% - Requires considerable assistance and frequent medical care  
40% - Disabled: requires special care and assistance  
30% - Severely disabled: hospitalization is indicated, death not imminent  
20% - Very sick, hospitalization necessary: active treatment necessary  
10% - Moribund, fatal processes progressing rapidly

**Note:** The Lansky Score will display for pediatrics aged less than 18.

100% - Fully active, normal  
90% - Minor restrictions in physically strenuous activity  
80% - Active, but tires more quickly  
70% - Both greater restriction of and less time spent in play activity  
60% - Up and around, but minimal active play; keeps busy with quieter activities  
50% - Can dress but lies around much of day; no active play; can take part in quiet play/activities  
40% - Mostly in bed; participates in quiet activities  
30% - In bed; needs assistance even for quiet play  
20% - Often sleeping; play entirely limited to very passive activities  
10% - No play; does not get out of bed  
Not Applicable (patient < 1 year old)  
Unknown

**Note:** This evaluation should be in comparison to the person's normal function, indicating how the patient's disease has affected their normal function.

**Cognitive Development:** (Complete for recipients 18 years of age or younger.) Select the choice that best describes the recipient's cognitive development just prior to the time of transplant. This field is **required**.

**Definite Cognitive Delay/Impairment** (verified by IQ score <70 or unambiguous behavioral observation)

**Probable Cognitive Delay/Impairment** (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence)

**Questionable Cognitive Delay/Impairment** (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties)

**No Cognitive Delay/Impairment** (no obvious indicators of cognitive delay/impairment)

**Not Assessed**

**Motor Development:** (Complete for recipients 18 years of age or younger.) Select the choice that best describes the recipient's motor development just prior to the time of transplant. This field is **required**.

**Definite Motor Delay/Impairment** (verified by physical exam or unambiguous behavioral observation)

**Probable Motor Delay/Impairment** (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence)

**Questionable Motor Delay/Impairment** (not judged to be more likely than not, but with some indication of motor delay/impairment)

**No Motor Delay/Impairment** (no obvious indicators of motor delay/impairment)

**Not Assessed**

**Working for income:** (Complete for recipients 19 years of age or older.) If the recipient was working for income just prior to the time of transplant, select **Yes**. If not, select **No**. If reporting the recipient's death, indicate if the recipient was working for income just prior to death. This field is **required**.

**Academic Progress:** (This field is **required** for recipients less than 18 years of age.) Select the choice that best describes the recipient's academic progress just prior to the time of transplant. If the recipient is less than 5 years old or has graduated from high school, select **Not Applicable < 5 years old/High School graduate or GED**.

**Within One Grade Level of Peers**

**Delayed Grade Level**

**Special Education**

**Not Applicable < 5 years old/High School graduate or GED**

**Status Unknown**

**Academic Activity Level:** (This field is **required** for recipients less than 18 years of age.) Select the choice that best describes the recipient's academic activity level just prior to the time of transplant. If the recipient is less than 5 years old or has graduated from high school, select **Not Applicable < 5 years old/High School graduate or GED**.

**Full academic load**

**Reduced academic load**

**Unable to participate in academics due to disease or condition**

**Not Applicable < 5 years old/High School graduate or GED**

**Status Unknown**

**Source of Payment:**

**Primary:** Select as appropriate to indicate the recipient's source of primary payment (largest contributor) for the transplant. This field is **required**.

**Private insurance** refers to funds from agencies such as Blue Cross/Blue Shield, etc. It also refers to any worker's compensation that is covered by a private insurer.

**Public insurance - Medicaid** refers to state Medicaid funds.

**Public insurance - Medicare FFS (Fee-for-Service)** refers to funds from the government in which doctors and other health care providers are paid for each service provided to a recipient. For additional information about Medicare, see <http://www.medicare.gov/Choices/Overview.asp>.

**Public insurance - Medicare & Choice (also known as Medicare Managed Care)** refers to funds from the government in which doctors and other health care providers are paid for each service provided to a recipient, along with additional benefits such as coordination of care or reducing-out-of-pocket expenses. Sometimes a recipient may receive additional benefits such as prescription drugs. For additional information about Medicare, see <http://www.medicare.gov/Choices/Overview.asp>.

**Public insurance - CHIP (Children's Health Insurance Program)**

**Public insurance - Department of VA** refers to funds from the Veterans Administration.

**Public insurance - Other government**

**Self** indicates that the recipient will pay for the cost of transplant.

**Donation** indicates that a company, institution, or individual(s) donated funds to pay for the transplant and care of the recipient.

**Free Care** indicates that the transplant hospital will not charge recipient for the costs of the transplant operation.

**Foreign Government, Specify** refers to funds provided by a foreign government (Primary only) Specify foreign country in the space provided. (**List of Foreign Country codes – See Appendix E**)

**Date of Measurement:** (Complete for recipients 18 years of age or younger.) Enter the date, using the 8-digit format of MM/DD/YYYY, the recipient's height and weight were measured.

**Height:** Enter the height of the recipient, just prior to the time of transplant, in feet and inches or centimeters. If the recipient's height is unavailable, select the appropriate status from the **ST** field (**Missing, Unknown, N/A, Not Done**). For recipients 18 years old or younger at the time of transplant, UNet will generate and display calculated percentiles based on the 2000 CDC growth charts. This field is **required**.

**Weight:** Enter the weight of the recipient, just prior to the time of transplant, in pounds or kilograms. If the recipient's weight is unavailable, select the appropriate status from the **ST** field (**Missing, Unknown, N/A, Not Done**). For recipients 18 years old or younger at the time of transplant, UNet will generate and display calculated percentiles based on the 2000 CDC growth charts. This field is **required**.

**BMI (Body Mass Index):** The recipient's BMI will display. For candidates less than 20 years of age at the time of transplant, UNet will generate and display calculated percentiles based on the 2000 CDC growth charts.

**Percentiles** are the most commonly used clinical indicator to assess the size and growth patterns of individual children in the United States. Percentiles rank the position of an individual by indicating what percent of the reference population the individual would equal or exceed (i.e. on the weight-for-age growth charts, a 5 year-old girl whose weight is at the 25th percentile, weighs the same or more than 25 percent of the reference population of 5-year-old girls, and weighs less than 75 percent of the 5-year-old girls in the reference population). For additional information about CDC growth charts, see <http://www.cdc.gov/>.

**Note:** Users who check the BMI percentiles against the CDC calculator may notice a discrepancy that is caused by the CDC calculator using 1 decimal place for height and weight and UNet using 4 decimal places for weight and 2 for height.

**Previous Transplants:** The three most recent transplant(s), indicated on the recipient's validated Transplant Recipient Registration (TRR) record(s), will display. Verify all previous transplants listed by organ type, transplant date and graft failure date.

**Note:** The three most recent transplants on record for this recipient will be displayed for verification. If there are any prior transplants that are not listed here, contact the UNet Help Desk at 1-800-978-4334 or [unethelpdesk@unos.org](mailto:unethelpdesk@unos.org) to determine if the transplant event is in the database.

**Viral Detection:**

**HIV Serostatus:** Select the serology results from the drop-down list. This field is **required**.

**Positive**  
**Negative**  
**Not Done**  
**UNK/Cannot Disclose**

Definition: Human Immunodeficiency Virus - Any of several retroviruses and especially HIV-1 that infect and destroy helper T cells of the immune system causing the marked reduction in their numbers that is diagnostic of AIDS.

**CMV Status:** Select the serology results from the drop-down list. This field is **required**.

**Positive**  
**Negative**  
**Not Done**  
**UNK/Cannot Disclose**

**HBV Core Antibody:** Select the serology results from the drop-down list. This field is **required**.

**Positive**  
**Negative**  
**Not Done**  
**UNK/Cannot Disclose**

Definition: Hepatitis B Virus - A sometimes fatal hepatitis caused by a double-stranded DNA virus (genus Orthohepadnavirus of the family Hepadnaviridae) that tends to persist in the blood serum and is transmitted especially by contact with infected blood (as by transfusion or by sharing contaminated needles in illicit intravenous drug use) or by contact with other infected bodily fluids (as during sexual intercourse) -- also called serum hepatitis.

**HBV Surface Antibody Total:** Select the serology results from the drop-down list. This field is **required**.

**Positive**  
**Negative**  
**Not Done**  
**UNK/Cannot Disclose**

**HBV Surface Antigen:** Select the serology results from the drop-down list. This field is **required**.

**Positive**  
**Negative**  
**Not Done**  
**UNK/Cannot Disclose**

Definition: Hepatitis B Virus - A sometimes fatal hepatitis caused by a double-stranded DNA virus (genus Orthohepadnavirus of the family Hepadnaviridae) that tends to persist in the blood serum and is transmitted especially by contact with infected blood (as by transfusion or by

sharing contaminated needles in illicit intravenous drug use) or by contact with other infected bodily fluids (as during sexual intercourse) -- also called serum hepatitis.

**HCV Serostatus:** Select the serology results from the drop-down list. This field is **required**.

**Positive**  
**Negative**  
**Not Done**  
**UNK/Cannot Disclose**

Definition: Hepatitis C Virus - A disease caused by a flavivirus that is usually transmitted by parenteral means (as injection of an illicit drug, blood transfusion, or exposure to blood or blood products) and that accounts for most cases of non-A, non-B hepatitis.

**EBV Serostatus:** Select the serology results from the drop-down list. This field is **required**.

**Positive**  
**Negative**  
**Not Done**  
**UNK/Cannot Disclose**

Definition: (Epstein-Barr Virus) - A herpesvirus (genus Lymphocryptovirus) that causes infectious mononucleosis and is associated with Burkitt's lymphoma and nasopharyngeal carcinoma -- abbreviation EBV; called also EB virus.

**Has the recipient ever had a diagnosis of HCC:** If the recipient has been diagnosed with HCC at anytime, select **Yes**. If the recipient has not been diagnosed with HCC, select **No**.

### Clinical Information: Transplant Procedure

**Multiple Organ Recipient:** Other organs that were reported as being transplanted in the Recipient Feedback, will display. Verify the other organs transplanted at this time are correct. If incorrect, contact the Help Desk.

**Were extra vessels used in the transplant procedure:** If extra vessels (vascular allografts) were used in the transplant procedure, as indicated on the Waitlist Removal, **YES** displays.

Vessel Donor ID: The Donor ID entered on the Waitlist Removal displays.

**Note:** Donor IDs entered for this question must be from deceased donors. All deceased donor extra vessels must be monitored due to the potential for disease transmission.

**Note:** If the extra vessels used in a transplant procedure are procured from a tissue processing organization, they are not reported in UNet.

**Procedure Type:** Verify the procedure type is correct.

**Whole Liver**  
**Partial Liver, remainder not Tx or Living Transplant**  
**Split Liver**  
**Whole Liver with Pancreas (Technical Reasons)**  
**Partial Liver with Pancreas (Technical Reasons)**  
**Split Liver with Pancreas (Technical Reasons)**

**Split Type:** If the **Procedure Type** is a **Partial** or **Split** type, select the specific type. This field is **required**.

**Partial**  
**Right Lobe Without Middle Hepatic Vein (segments 5,6,7,8)**  
**Right Lobe with Middle Hepatic Vein (segments 4,5,6,7,8)**  
**Left Lobe (segments 2,3,4)**



**Left Lateral (segments 2,3)**

**Left Trisegment (segments 1,2,3,4,5,8)**

**Right trisegment with middle hepatic vein (segments 1, 4, 5, 6)**

**Split**

**Left Lobe In Situ (segments 2,3,4)**

**Left Lobe on the Bench (segments 2,3,4)**

**Left Lobe with Caudate In Situ (segments 1,2,3,4)**

**Left Lobe with Caudate on the Bench (segments 1,2,3,4)**

**Left Lateral Segment In Situ (segments 2,3)**

**Left Lateral Segment on the Bench (segments 2,3)**

**Right Lobe Without Middle Hepatic Vein In Situ (segments 5,6,7,8)**

**Right Lobe Without Middle Hepatic Vein on the Bench (segments 5,6,7,8)**

**Right Lobe with Middle Hepatic Vein In Situ (segments 4,5,6,7,8)**

**Right Lobe with Middle Hepatic Vein on the Bench (segments 4,5,6,7,8)**

**Preservation Information:**

**Total Cold Ischemia Time (If pumped, include pump time):** The number of hours between the time of preservation of the organ and the time of removal from cold storage. If the time is unavailable, select the appropriate status from the **ST** field (**Missing, Unknown, N/A, Not Done**). This field is **required**.

**Note:** Enter the time in hours and decimal parts of an hour. For example, 1 hour should be entered as "1", "1.0" or "1.00"; 1 hour and 30 minutes should be entered as "1.5" or "1.50" **not "1.30"**.

To report the minutes, divide the number of minutes into 60 and record 2 decimal places. Example: 7hrs 19 minutes = 7.32 (60 divided by 19 =.32)

**Note:** Select **N/A** from the **ST** field for Preservation Information if the recipient was removed from the waiting list with a code 21, indicating the recipient died during the transplant procedure.

**Risk Factors:** For each of the risk factors listed, indicate the recipient's history of the risk factor at the time of this transplant.

**Previous Abdominal Surgery:** If the recipient had any abdominal surgery prior to this transplant, select **Yes**. If not, select **No**. If unknown, select **UNK**. This field is **required**.

**Portal Vein Thrombosis:** If the recipient has experienced portal vein thrombosis prior to this transplant, select **Yes**. If not, select **No**. If unknown, select **UNK**. This field is **required**.

**Transjugular Intrahepatic Portacava Stint Shunt:** If the recipient has required TIPSS prior to this transplant, select **Yes**. If not, select **No**. If unknown, select **UNK**. This field is **required**.

**Clinical Information: Post Transplant**

**Pathology Conf. Liver Diag. of Hospital Discharge:** Select the most definitive primary liver diagnosis, based on clinical and pathological evidence on the *native/replaced* liver. **Be specific**. If the diagnosis is cirrhosis or hepatitis, choose the diagnosis that indicates the correct etiology and if the hepatitis is chronic or acute. If an **Other** code is selected, enter the specific diagnosis in the space provided. This is to confirm the reason for transplant. This information will display as read-only on TRF records. This field is **required** (**List of Pathology-Confirmed Diagnosis codes – See [Appendix L](#)**)

**Note:** Enter the same information that was entered for the **Primary Diagnosis** at the time of hospital discharge if the recipient was removed from the waiting list with a code 21, indicating the recipient died during the transplant procedure.

**Graft Status:** If the liver graft is functioning, select **Functioning**. If the graft is not functioning at the time of hospital discharge or time of report, select **Failed**. If failed, complete the remainder of this section. This field is **required**.



**Note:** Select **Functioning** if the recipient was removed from the waiting list with a code 21, indicating the recipient died during the transplant procedure.

**Note:** If death is indicated for the recipient, and the death was a result of some other factor unrelated to graft failure, select **Functioning**.

If **Failed**, provide the following information:

**Date of Failure:** Enter the date of graft failure using the standard 8-digit numeric format of MM/DD/YYYY.

**Causes of Graft Failure:** For each cause of graft failure listed, select **Yes**, **No**, or **UNK**. If **Other Specify** is selected, enter the cause of graft failure in the space provided.

**Primary Non-Function**  
**Hepatic Artery Thrombosis**  
**Other Vascular Thrombosis**  
**Hepatitis: DeNovo**  
**Hepatitis: Recurrent**  
**Recurrent Disease (non-Hepatitis)**  
**Acute Rejection**  
**Diffuse Cholangiopathy**  
**Infection**  
**Other, Specify**

If **Vascular Thrombosis** is selected for pediatric recipients, complete the following information:

**Hepatic arterial thrombosis:** If the recipient had a hepatic arterial thrombosis, select **Yes**. If not, select **No**. If unknown, select **Unknown**.

**Hepatic outflow obstruction:** If the recipient had hepatic outflow obstruction, select **Yes**. If not, select **No**. If unknown, select **Unknown**.

**Portal vein thrombosis:** If the recipient had portal vein thrombosis, select **Yes**. If not, select **No**. If unknown, select **Unknown**.

**Did patient have any acute rejection episodes between transplant and discharge:** If the recipient had any acute rejection episodes between transplant and discharge, select a **Yes** choice. If not, select **No**. If a **Yes** choice is selected, then indicate if a biopsy was done to confirm acute rejection. This field is **required**.

**Yes, at least one episode treated with anti-rejection agent**  
**Yes, none treated with additional anti-rejection agent**  
**No**

#### Treatment

#### Immunosuppressive Information

**Are any medications given currently for maintenance or anti-rejection:** If medications have been given to the recipient for maintenance or anti-rejection during the time between transplant and hospital discharge, or 6 weeks post-transplant if the recipient has not been discharged, select **Yes**. If not, select **No**. If **Yes**, complete the sections below. This field is **required**.

#### Immunosuppressive Medications

For each of the immunosuppressive medications listed, select **Ind.(Induction)**, **Maint (Maintenance)** or **AR (Anti-rejection)** to indicate all medications that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box blank.

**Induction (Ind.)** immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (e.g., Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as rejection therapy if used for this reason. For each induction medication indicated, enter the total number of days the drug was actually administered in the space provided. For example, if Simulect or Zenapax was given in 2 doses a week apart then the total number of days would be 2, even if the second dose was given after the patient was discharged.

**Maintenance (Maint)** includes all immunosuppressive medications given before, during or after transplant for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (e.g., Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

**Anti-rejection (AR)** immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (e.g., Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (e.g., from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

**Note:** As further clarification, drugs that are used with the intention to maintain recipients long-term are medications such as Tacrolimus, Cyclosporine, Azathioprine, Mycophenolate Mofetil and Prednisone. These maintenance medications should not be listed as AR medications to treat acute rejection. When patients have a true acute rejection, they are given anti-rejection medication such as steroids, OKT3, ATG, Simulect and Zenapax, in addition to the maintenance medications. These are the medications that should be selected as anti-rejection.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select **Ind.**, **Maint**, or **AR** next to **Other Immunosuppressive Medication** field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

If the number of days is unavailable, select the appropriate status from the applicable **Status** field (**Missing**, **Unknown**, **N/A**, **Not Done**).

#### Other Immunosuppressive Medications

For each of the immunosuppressive medications listed, select **Ind.(Induction)**, **Maint (Maintenance)** or **AR (Anti-rejection)** to indicate all medications that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box blank.

**Induction (Ind.)** immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (e.g., Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as rejection therapy if used for this reason. For each induction medication indicated, enter the total number of days the drug was actually administered in the space provided. For example, if Simulect or Zenapax was given in 2 doses a week apart then the total number of days would be 2, even if the second dose was given after the patient was discharged.

**Maintenance (Maint)** includes all immunosuppressive medications given before, during or after transplant for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (e.g., Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

**Anti-rejection (AR)** immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (e.g., Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (e.g., from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

**Note:** As further clarification, drugs that are used with the intention to maintain recipients long-term are medications such as Tacrolimus, Cyclosporine, Azathioprine, Mycophenolate Mofetil and Prednisone. These maintenance medications should not be listed as AR medications to treat acute rejection. When patients have a true acute rejection, they are given anti-rejection medication such as steroids, OKT3, ATG, Simulect and Zenapax, in addition to the maintenance medications. These are the medications that should be selected as anti-rejection.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select **Ind.**, **Maint**, or **AR** next to **Other Immunosuppressive Medication** field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

If the number of days is unavailable, select the appropriate status from the applicable **Status** field (**Missing, Unknown, N/A, Not Done**).

### Investigational Immunosuppressive Medications

For each of the immunosuppressive medications listed, select **Ind.(Induction)**, **Maint (Maintenance)** or **AR (Anti-rejection)** to indicate all medications that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box blank.

**Induction (Ind.)** immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as rejection therapy if used for this reason. For each induction medication indicated, enter the total number of days the drug was actually administered in the space provided. For example, if Simulect or Zenapax was given in 2 doses a week apart then the total number of days would be 2, even if the second dose was given after the patient was discharged.

**Maintenance (Maint)** includes all immunosuppressive medications given before, during or after transplant for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (e.g., Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

**Anti-rejection (AR)** immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs

(example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

**Note:** As further clarification, drugs that are used with the intention to maintain recipients long-term are medications such as Tacrolimus, Cyclosporine, Azathioprine, Mycophenolate Mofetil and Prednisone. These maintenance medications should not be listed as AR medications to treat acute rejection. When patients have a true acute rejection, they are given anti-rejection medication such as steroids, OKT3, ATG, Simulect and Zenapax, in addition to the maintenance medications. These are the medications that should be selected as anti-rejection.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select **Ind.**, **Maint.**, or **AR** next to **Other Immunosuppressive Medication** field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

If the number of days is unavailable, select the appropriate status from the applicable **Status** field (**Missing**, **Unknown**, **N/A**, **Not Done**).

### **Drug Codes**

#### **Immunosuppressive Medications**

Steroids (Prednisone, Methylprednisolone, Solumedrol, Medrol, Decadron)

Atgam (ATG)

OKT3 (Orthoclone, Muromonab)

Thymoglobulin

Simulect - Basiliximab

Zenapax - Daclizumab

Azathioprine (AZA, Imuran)

EON (Generic Cyclosporine)

Gengraf (Abbott Cyclosporine)

Other generic Cyclosporine, specify brand:

Neoral (CyA-NOF)

Sandimmune (Cyclosporine A)

CellCept (Mycophenolate Mofetil; MMF)

Generic MMF (Generic CellCept)

Prograf (Tacrolimus, FK506)

Generic Tacrolimus (Generic Prograf)

Nulojix (Belatacept)

Astagraf XL (Extended Release Tacrolimus)

Sirolimus (RAPA, Rapamycin, Rapamune)

Myfortic (Mycophenolate Sodium)

#### **Other Immunosuppressive Medications**

Campath - Alemtuzumab (anti-CD52)

Cyclophosphamide (Cytoxan)

Leflunomide (LFL, Arava)

Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)

Other Immunosuppressive Medication, Specify

Rituximab

**Investigational Immunosuppressive Medications**

Zortress (Everolimus)

Other Immunosuppressive Medication, Specify